Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment

Giovanni C Actis, Rinaldo Pellicano

Incurable inflammatory disorders of the gut. Some 10% run a downhill course, requiring emergency medical support and often surgery; another small subset are monogenic, and, threatening pediatric patients, are the challenge of these days. The majority of the IBDs, however, are polygenic low-penetrance diseases, running a lifetime waxing-and-waning course. The prevalent trend is towards a slow worsening and steady cost increase. Each and all drugs of the available arsenal exhibit strengths and weaknesses: Mesalamines are chiefly effectively for mild-moderate colitis, and do not work in Crohn’s; steroids do not control some 40% of the ulcerative colitis cases, and are not indicated for Crohn’s; thiopurines are effective in the maintenance of the IBDs but do not prevent relapses on withdrawal; biologics are still being used empirically (not monitored) causing further increase of their cost over that of hospitalization. Against all these caveats, two simple rules still hold true: Strict adherence maintenance and avoidance of colitogenic drugs. This matter is expanded in this minireview.

Key words: Inflammatory bowel disease; Therapy; Cost containment; Budget; Treatment adherence; Inflammatory bowel disease managed care

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Cost-effective maintenance of remission of inflammatory bowel diseases (IBD) is a traditionally unsolved challenge for care-takers and budget supervisors. The newly released (biologic) formulations, though purported to act as disease terminators, have failed to pay back their initial cost. We have faced the issue by reappraising initial simple tenets and found the following: (1) usually, uncomplicated IBD rests in remission by using cheap traditional drugs, provided the indication is correct, and, chiefly, that adherence is tightly maintained. Non compliant IBD patients cost manifold the compliant ones, and are the main cause of budget distortion; and (2) third-party drugs (nonsteroidal anti-inflammatory drugs, e.g., should be avoided. A frozen steady-state is the regime to
Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. *World J Gastrointest Pharmacol Ther* 2017; 8(2): 114-119 Available from: URL: http://www.wjgnet.com/2150-5349/full/v8/i2/114. htm DOI: http://dx.doi.org/10.4292/wjgpt.v8.i2.114

---

**EPIDEMIOLOGY**

The Italian health service does not cover medical expenses in full, but requires patients to partially contribute to extents that vary according to income and social positions. Patients suffering from chronic incurable disease including inflammatory bowel diseases (IBD) may apply for full coverage. Hence, the number of applications may yield an estimate of the prevalence of IBD in Italy. Such estimates, dating back to 2009\(^1\), are showing an IBD prevalence in Italy of 177-254 cases/10\(^5\). Regional incidence data of pooled Crohn’s disease (CD) and ulcerative colitis (UC) yield figures between 2.7 and 13 cases per 10\(^5\) per year. A recently published Survey of Italian Gastroenterology Societies\(^2\) indicates that: (1) Despite a recent increase between 1970 and 1990, the incidence of IBD in Italy is still exceeded by the Northern Europe figures; (2) Pediatric incidence figures of both IBD phenotypes has gone up from 0.89 to 1.39 between 1996 and 2003; (3) With UC being slightly more frequent in males, general data confirm the existence of two incidence peaks, at 25/35 years and around the sixth life decade; and (4) An increased family risk, various extra-intestinal manifestations, and the association with immune-mediated disease (multiple sclerosis, psoriasis, and celiac disease just as examples) all mark the clinical IBD presentations.

**MORBIDITY AND MORTALITY**

Large population studies demonstrate that active IBD does significantly reduce quality of life, with young fertile women being mostly affected\(^2,4\). In Italy, IBD-dependent disability is quantified in classes from the lowest 15% to the maximum of 70% (fourth class) if surgery has been needed. By contrast, IBD does not seem to significantly reduce life expectancy; notably, however, mortality is estimated to be increased in the first year of diagnosis as well as in patients younger than 30 years\(^5\).

**ADMISSIONS**

IBD patients do need hospitalization more frequently than the general population, with most of admissions ending in surgery. About 4.6%-7.5% of UC cases and 36% of CD patients become operated at 5 years. The figure is 17% for pediatric cases\(^6\).

---

**THERAPEUTIC ARSENAL**

There are two main challenges in the management of IBD, and these divide the list of the available drugs into two distinct chapters: induction of a response, and maintenance of the remission.

**Mesalamines and its derivatives**

Pioneered by Nanna Svartz studies on salazopyrin, mesalamines and its derivatives have been a mainstay for IBD treatment for the last 60 years. The modern version of salazopyrin, 5-aminosalycilic acid (5-ASA), has been tested in a large population study employing a range of doses between 1 and 4 daily g. Such dosages have shown effectiveness in CD. A study already completed in 2005 showed that post-operative administration of omidazole could reduce relapse rates from 37% to 7%\(^9\). By contrast, UC has proven unresponsive to antibiotics\(^10\). Ciprofloxacin and metronidazole are advantageous for CD; this issue is exhaustively illustrated in a freshly updated review\(^11\).

**Antibiotics**

Some antibiotic molecules of the imidazole class have shown effectiveness in CD. A study already completed in 2005 showed that post-operative administration of omidazole could reduce relapse rates from 37% to 7%\(^9\). By contrast, UC has proven unresponsive to antibiotics\(^10\). Ciprofloxacin and metronidazole are advantageous for CD; this issue is exhaustively illustrated in a freshly updated review\(^11\).

**Corticosteroids**

Population studies have shown that 34% and 44% of UC and CD patients, respectively, need a variable number of steroid courses to achieve remission\(^12\); by contrast, steroids are contraindicated for remission maintenance.

**Thiopurines**

Experience achieved over the last 30 years has consistently indicated that thiopurines are effective in the maintenance of remission of both IBD phenotypes. A classic controlled study published in 1980, including steroid-dependent and/or fistulizing CD patients, showed that 31% experienced fistula closure, and 75% were weaned from steroids if treated with 6-mercaptopurpine (6-MP); these figures were respectively 6% and 36% in the placebo-treated subgroup\(^13\). By contrast, evidence favoring the use of thiopurines to treat UC has lingered a little behind: A recent study from us has shown that of 127 Italian patients who had had their azathioprine withdrawn, one-third, 50%, and two-thirds did relapse
RESCUE TREATMENTS FOR REFRACTORINESS TO CONVENTIONAL DRUGS

Preliminary work published in 1990 showed that cyclosporine, a fungal derived peptide able to inhibit T-lymphocyte responses, could achieve remission in a significant proportion of patients facing colectomy for refractory acute UC[17]. Later in 1994 such initial data were then confirmed in a controlled fashion[18]. The number of refractory colitic patients that had received cyclosporine was estimated to reach the number of 700 in 2005[19]. Interestingly, an English survey showed that only 7%-8% of all hospitalized IBD patients do receive cyclosporine; however, if asked whether they would opt to be treated, their positive responses often outweigh their own doctors’ intentions[20]. The literature consistently indicates that cyclosporine effectively avoids immediate colectomy in 60% to 80% of steroid refractory UC patients; subsequent ability to maintain remission may fall around 60%, and is potentiated by the concomitant administration of a thiorapine[21]. In the suggestion of a leading center[22] cyclosporine must be considered a mainstay treatment for refractory colitis. Along this line, we have recently reviewed the pharmacologic profiles of cyclosporine, mesalamine, and thiopurines on the basis of the experience of treatment of 100 consecutive patients between 1991 and 2007. We succeeded in confirming the data discussed above, and stressed the need for further efforts in the direction to improve the pharmacologic profile of these drugs[23]. As of today, official position statements[24] hold that cyclosporine is as effective as infliximab to control severe refractory colitis, whereas it is not indicated for Crohn disease.

Recent Cochrane reviews have shown that tumor necrosis factor (TNF)-inhibitors (chiefly infliximab and adalimumab) can effectively treat steroid-dependence and fistula formation in CD[25]; similar but weaker evidence (owing to patient heterogeneity) have been published for UC[26]. Such favorable evidence seems not to be reflected in real-world practice, whereby it is estimated that not more than 15% of candidate IBD patients do receive an anti-TNF molecule[27]. A recent in-depth analysis conducted in Europe[28] has found that the healthcare costs for IBD are mainly influenced by medication, chiefly anti-TNF molecules, despite the potential of these measures to restrict resort to hospitalization; notably, similar research carried out in Canada has come to the same conclusions[29]. The implications of such findings can probably be re-shaped by the evidence that in losers of response, replacement of a blind dose escalation with therapeutic drug monitoring (test-based strategy) can lead to major cost saving[30].

THE IBDS: NATURAL HISTORY

Before the release of drugs such as mesalamines and steroids, and the availability of adequate resuscitation and surgical techniques, UC turned out to be a rather ominous disease: 33% risk of death in the first year; 12% mortality rate at relapse; the cumulative death risk 20 years following diagnosis was 40%; 40 years after diagnosis the colon carcinoma risk was 40%[31]. The scenario of 1983[32], namely 30 years after Truelove and Witts demonstration of the effectiveness of steroids had begun to change, contradictory areas persisted. The survival rate of those diagnosed with mild/moderate disease matched that of controls; yet, severe disease presentation still entailed mortality rates of 31% as distributed in the first 4 years. Nowadays, severe UC is expected to present with a frequency of 10-15% at any time of disease course: According to updated evidence the expected mortality is null, but sporadic fatal cases cannot be excluded[33].

Some 50% to 80% of the patients run a waxing-and-waning course, whereas a chronic active course may be observed in 15%-30%[24]. According to a reference publication: Young age, previous relapses, and presence of residual histologic disease (plasmacytosis) are all predictors of relapse[35]. The frequencies of resort to surgery are reported to range between 9.6% after 5 years and 31% after 18 years[36].

The natural history of CD is driven by disease localization and its strength to evolve. In population studies, a non-stenosing pattern, a stenosing pattern, and a penetrating course may be described with frequencies of 70%, 17%, and 13% respectively. In the follow-up, a switch to a stenosing pattern and to a penetrating one was recorded in 27% and 28% respectively. Some 50% of the patients did exhibit an ileal localization, an ileo-colic one by contrast affected the other half[37].

The data of two population studies including some 600 patients were rewarding: 10%-30% of the cases may expect a relapse in the first year of diagnosis; 15%-25% linger in a condition of low disease activity, whereas remission might remain the outcome in 50%-65%. Resort to surgery is a likely outcome in CD: 30% probability in the first year; the patient majority undergoes an operation after 20 years of disease. Those with ileo-cecal disease are the most likely to undergo operation: Specifically, the risk of an emicolectomy is 35% after 10 years[38,39].

THE BUDGET OF UC

According to a study of 1992, the annual cost per
A patient was dollars 1488\(^{[40]}\). The 24% of this sum included three items of 8% each: The diagnostic algorithm, the out-patient services, the drug cost; direct and indirect costs of hospitalization made the remaining 47%. Two further data are to be emphasized: In a sample observation year, 39% of the bills charged to providers had been meant to cover the needs of only 2% of the insured clients (the subset with the worst disease forms), whereas from another point of evaluation, the majority of the insured subjects were responsible for less than 7% of the costs.

This data are a spy of the heterogeneity of the sources of expense in an IBD population: As a general rule, firmly controlled disease costs dramatically less than the chronically uncontrolled presentations that often face surgery.

This trend of surgery to make the most part of the budget is further strengthened by several factors. The three-steps reconstructive proctectomy with pouch anal anastomosis has significantly benefited patients by ensuring digestive tract continuity, but, making the patient hospital-dependent for 6 mo, have raised the costs sky-high. One other factor is the natural tendency of the disease to worsen, to increase the need for drugs and care, and to become laden with complications, including neoplasia.

The need to aggressively maintain the disease in remission to minimize costs stems clear from the above discussion\(^{[41]}\). To achieve this goal one may need a costly drug armamentarium (including biologic drugs in the last years) but most American providers do retain that this cost can be paid back by the advantages of managing a disease in remission. Direct costs (hospitalization) and indirect costs (drugs, sick leaves, family disruption) are to be chiefly accounted for in an unstable disease, and can be abolished by its stabilization\(^{[42]}\).

**TWO MAIN FACTORS THREATENING REMISSION MAINTENANCE IN IBD**

**Lack of adherence**

Among the main missions of private care systems relies the identification and control of conditions of major cost. The American health care system has long pursued this goal, eventually collecting a large wealth of data. The essential message is that disease management is mostly expensive in unstable phases\(^{[43]}\). Lack of compliance has been identified as one of the capital factors in the loss of IBD remission. This matter may be discussed by differentiating four main topics: (1) The facts; (2) The causes and modalities of non-compliance; (3) The costs; and (4) Possible counter measures.

**Facts:** One hundred UC patients had mesalamine prescribed and were then followed prospectively for two years, with checkups at 6, 12, and 24 mo; the re-appearance of at least 4 bloody urgent stools a day was defined as relapse. Non-adherent patients showed a 5-fold higher relapse rate; at 24 mo, 39% of non-adherent subjects were in remission, as opposed to 89% of adherent ones\(^{[44]}\). IBD patients seem to be maximally keen on non-compliance, as suggested by the following data. The adherence percentages during clinical trials may attain 80%; this contrasts with data in population studies, whereby the majority of subjects in remission opt for taking the risk of relapse for non-compliance than to accept the burden of a daily drug administration\(^{[45]}\).

**Causes and modalities:** Pooled results from different studies indicated that favoring factors for non-adherence were a condition of male-single, and a left-sided colitis; a colonoscopy in the preceding 2 years and being married were opposing factors, instead\(^{[46]}\). When requested to declare their reasons for non-adherence, the answers were: Forgetfulness (50%); two many daily administrations (30%); doubts on the indication (20%).

**Costs:** Non-adherence entails extra-costs: increased morbidity; rescue drugs are more expensive; risk for complications including cancer; sick leaves; stress and family disruption. In pure terms of numbers, one should bear in mind that any single failure of a mesalamine prescription costs dollars 11500 per person\(^{[41]}\).

**Countermeasures:** According to the experience of American health providers, patient counseling and release of single-dose drugs are the only worthy measures to reduce non-adherence.

**Improper use of third-party drugs**

Nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics have long been suspected as factors of IBD reactivation or de-novo IBD causation. Recently, our attention got specifically concentrated on the role of macrolide antibiotics. Capable to favor gut colonization by Candida, these antibiotics might increase intestinal permeability, a favorable ground for IBD triggering\(^{[47]}\). In our out-patient clinic, it has become routine to warn referring doctors and patients against the unjustified use of macrolide molecules or NSAIDs. Dental surgery and orthopedic traumatology remain the main indication source for these drugs, and merit careful surveillance by academic gastroenterology centers.

**CONCLUSION**

While the prevalence of IBD is roughly stable in the Western World, the figures are on the rise of its incidence in two other contexts: Pediatric IBD and migrants.

As an incurable chronic disorder capable to disable the GI tract, IBD can easily impact a country’s budget. In moments of financial restriction, care providers may duly concentrate their attention on the list of “traditional therapies”, seeking optimization (increasing therapeutic
effects while diminishing costs). Current evidence recommends now that this optimization path be based on the evidence that the easiest at maintenance and less costly are the quiescent phases of IBD. Thus, such phases are to be vigorously achieved and tenaciously maintained, adhering to the following rules: (1) Pursue remission by early giving steroids and/or mesalazines at full doses. Proceed to a prompt and rapid steroid tapering once clinical remission is achieved. Continue mesalazines in most of the cases; (2) Respecting safety rules, use thiopurines as the best option in maintaining remission, smartly minding the strong synergism that might develop with mesalazines, both in terms of therapeutic or toxic effects; (3) As said above, patients’ compliance must strictly be monitored and corrected, as faulty compliance has been shown to be a strongly negative factor in remission maintenance and cost control; (4) Instruct family physicians and patients to carefully consider prescriptions of antibiotics and NSAIDs: Though some antibiotics may be therapeutic for IBD’s, some other commonly prescribed formulations (macrolides) may activate or generate de-novo IBD, as NSAIDs can do; and (5) Bear in mind that average IBD can be controlled by the timely use of correctly dosed traditional molecules: Sometime the need for costly therapies is provoked by the late or inadequate use of common treatments.

To give the reader an idea of how important it might be to fully exploit conventional therapies before resorting to biologic strategies, we like to implement the end of this paragraph by showing the cost for one day of treatment with the molecules mentioned in this text (expressed in euro) as reported by us in 2010: Mesalazine: 3.06; first-generation steroids: 1.02; thiopurines 0.87; infliximab/adalimumab: 894/1675.

REFERENCES

1 Turisi A, Elisei W, Picchio M. Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting. Eur J Intern Med 2013; 24: 852-856 [PMID: 23867759 DOI: 10.1016/j.ejim.2013.06.005]
2 Buscarini E, Conte D, Cannizzaro R, Bazzoli F, De Boni M, Delle Fave G, Farinati F, Raveli P, Testoni PA, Lisiero M, Spoltero P. White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. Dig Liver Dis 2014; 46: 579-589 [PMID: 24913902 DOI: 10.1016/j.dld.2014.02.019]
3 Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, Sperber A, Toner B, Drossman DA. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. J Gastroenterol 2001; 96: 1822-1830 [PMID: 11498936 DOI: 10.1111/j.1572-0241.2001.00387.x]
4 Kohn A, Fano V, Monteverdibianesi R, Davoli M, Marrollo M, Stasi E, Perucci C, Pranterca C. Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: a 10-year cohort study. Dig Liver Dis 2012; 44: 369-374 [PMID: 22197692 DOI: 10.1016/j.dld.2011.11.009]
5 Visco O, Bagnardi V, Stattin GC, Annesse V, Frieri G, Kornbluth A, Geller I, Bauer J, Galler G. Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845 [PMID: 8196726 DOI: 10.1056/NEJM199406303302601]
6 García-López S, Gomollón García-Fernández S, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28: 607-614 [PMID: 16373009 DOI: 10.1016/S0210-5705(05)7152-5]
7 Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther 2008; 27 Suppl 1: 1-8 [PMID: 18307643 DOI: 10.1111/j.1365-2036.2008.03605.x]
8 Peyrin-Biroulet L. Que deviennent les colites aiguës graves traitées médicalement avec succès? Colon Rectum 2008; 2: 17-21 [DOI: 10.1007/s11725-008-0072-1]
9 Cheiftetz AS, Stern J, Garul S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol 2011; 45: 107-112 [PMID: 20679905 DOI: 10.1097/MCG.0b013e3181e8834d]
10 Actis GC, Rosina F, Pollicano R, Rizzuto M. An aggressive medical approach for inflammatory bowel disease: clinical challenges and therapeutic profiles in a retrospective hospital-based series. Curr Clin Pharmacol 2012; 7: 209-213 [PMID: 22564119 DOI: 10.2174/1574
Actis GC et al. Remission of inflammatory bowel disease

36 Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis—based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 158-163 [PMID: 3967834 DOI: 10.1136/gut.26.2.158]

37 Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782 [PMID: 11709511 DOI: 10.1136/gut.49.6.777]

38 Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995; 30: 699-706 [PMID: 7481535 DOI: 10.3109/003

39 Loftus EV, Scheinbold P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60 [PMID: 11856078 DOI: 10.1046/j.1365-2636.2002.01140.x]

40 Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309-317 [PMID: 1607607 DOI: 10.1097/00044836-199206000-00009]

41 Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface 2006; 19: 39-46, 56 [PMID: 17117598]

42 Tindall VN, Boltri JM, Willem SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007; 13: S2-12; quiz S13-14 [PMID: 17874873]

43 Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care 2016; 22: S51-S60 [PMID: 27269903]

44 Kane S, Hsu D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43 [PMID: 12543288 DOI: 10.1016/100s002-9343(02)1383-9]

45 López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 Suppl 3: 49-54 [PMID: 16961745 DOI: 10.1111/j.1365-2636.2006.03060.x]

46 Kane SV, Cohen RD, Aikens J, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-2933 [PMID: 11693328 DOI: 10.1111/j.1572-0241.2001.04683.x]

47 Samonis G, Maraki S, Anotoliakas N, Anatoliakati M, Apostolakou H, Margioris AN, Tselenitis Y, Kontoyiannis DP. Effects of erythromycin, clarithromycin, roxithromycin and azithromycin on murine gut colonization by Candida albicans. Med Mycol 2002; 40: 139-142 [PMID: 12058726 DOI: 10.1080/mmy.40.2.139.142]

48 Actis GC, Marzano A, Pellicano R, Rizzetto M. How important is mesalamine in the maintenance of steroid-refractory colitis? Inflamm Bowel Dis 2008; 14: 1026 [PMID: 18338772 DOI: 10.1002/ibd.20422]

49 Actis GC, Pellicano R, Fadda M, Rosina F. Antibiotics and non-steroidal anti-inflammatory drugs in outpatient practice: indications and unwanted effects in a gastroenterological setting. Curr Drug Saf 2014; 9: 133-137 [PMID: 24468990 DOI: 10.2174/157488630664614 0120902533]

50 Reddy SS, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005; 100: 1357-1361 [PMID: 15929770 DOI: 10.1111/j.1572-0241.2005.04849.x]

51 Actis GC, Rosina F. Outpatient care for inflammatory bowel disease at a primary referral hospital in Turin. Minerva Gastroenterol Dietol 2010; 56: 27-34 [PMID: 20197222]

P- Reviewer: Hokama A, Jerardi E, Mulder CJ 
S- Editor: Kong JX 
L- Editor: A 
E- Editor: Lu YJ
